CN104768572B - 葡萄球菌凝固酶抗原及其使用方法 - Google Patents

葡萄球菌凝固酶抗原及其使用方法 Download PDF

Info

Publication number
CN104768572B
CN104768572B CN201380033361.XA CN201380033361A CN104768572B CN 104768572 B CN104768572 B CN 104768572B CN 201380033361 A CN201380033361 A CN 201380033361A CN 104768572 B CN104768572 B CN 104768572B
Authority
CN
China
Prior art keywords
coa
vwbp
staphylococcal
protein
domains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380033361.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN104768572A (zh
Inventor
莫利·麦克多夫
安德里亚·迪登
艾利斯·陈
卡拉·艾默罗
多米尼克·米西亚卡斯
奥拉夫·施内温德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of CN104768572A publication Critical patent/CN104768572A/zh
Application granted granted Critical
Publication of CN104768572B publication Critical patent/CN104768572B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201380033361.XA 2012-04-26 2013-03-14 葡萄球菌凝固酶抗原及其使用方法 Expired - Fee Related CN104768572B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261638831P 2012-04-26 2012-04-26
US61/638,831 2012-04-26
US201261674619P 2012-07-23 2012-07-23
US61/674,619 2012-07-23
PCT/US2013/031695 WO2013162746A1 (en) 2012-04-26 2013-03-14 Staphylococcal coagulase antigens and methods of their use

Publications (2)

Publication Number Publication Date
CN104768572A CN104768572A (zh) 2015-07-08
CN104768572B true CN104768572B (zh) 2021-08-24

Family

ID=49483731

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380033361.XA Expired - Fee Related CN104768572B (zh) 2012-04-26 2013-03-14 葡萄球菌凝固酶抗原及其使用方法

Country Status (13)

Country Link
US (3) US9968668B2 (enExample)
EP (2) EP2844275B1 (enExample)
JP (2) JP6670106B2 (enExample)
CN (1) CN104768572B (enExample)
AU (1) AU2013252883B2 (enExample)
BR (1) BR112014026861A2 (enExample)
CA (1) CA2910319C (enExample)
DK (1) DK2844275T3 (enExample)
ES (1) ES2806945T3 (enExample)
HR (1) HRP20201127T1 (enExample)
NZ (1) NZ702285A (enExample)
PL (1) PL2844275T3 (enExample)
WO (1) WO2013162746A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
NZ702285A (en) * 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
ES2776179T3 (es) * 2012-11-06 2020-07-29 Medimmune Llc Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
US9353189B2 (en) * 2014-01-24 2016-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
JP7117244B2 (ja) * 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127032A1 (en) * 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3949064A (en) 1973-10-26 1976-04-06 Baxter Laboratories, Inc. Method of detecting antigens or antibodies
US4174384A (en) 1975-06-30 1979-11-13 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4338298A (en) 1980-04-04 1982-07-06 Endowment And Research Foundation At Montana State University Vaccine for passive immunization against enteric colibacillosis and method of use
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
NL8200523A (nl) 1982-02-11 1983-09-01 Univ Leiden Werkwijze voor het in vitro transformeren van planteprotoplasten met plasmide-dna.
US4748018A (en) 1984-02-07 1988-05-31 Stolle Research & Development Corp. Method of passive immunization of mammals using avian antibody
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5221605A (en) 1984-10-31 1993-06-22 Igen, Inc. Luminescent metal chelate labels and means for detection
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
AU622104B2 (en) 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US4952500A (en) 1988-02-01 1990-08-28 University Of Georgia Research Foundation, Inc. Cloning systems for Rhodococcus and related bacteria
AU623642B2 (en) 1988-03-24 1992-05-21 University Of Iowa Research Foundation, The Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
US5858652A (en) 1988-08-30 1999-01-12 Abbott Laboratories Detection and amplification of target nucleic acid sequences
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
SE8901687D0 (sv) 1989-05-11 1989-05-11 Alfa Laval Agri Int Fibronectin binding protein as well as its preparation
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US7705215B1 (en) 1990-04-17 2010-04-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5550318A (en) 1990-04-17 1996-08-27 Dekalb Genetics Corporation Methods and compositions for the production of stably transformed, fertile monocot plants and cells thereof
US5322783A (en) 1989-10-17 1994-06-21 Pioneer Hi-Bred International, Inc. Soybean transformation by microparticle bombardment
US5484956A (en) 1990-01-22 1996-01-16 Dekalb Genetics Corporation Fertile transgenic Zea mays plant comprising heterologous DNA encoding Bacillus thuringiensis endotoxin
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
CA2059693C (en) 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5610042A (en) 1991-10-07 1997-03-11 Ciba-Geigy Corporation Methods for stable transformation of wheat
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
NZ251621A (en) 1992-03-26 1996-04-26 Microcarb Inc Polyclonal antibodies to shiga-like toxins
US5591616A (en) 1992-07-07 1997-01-07 Japan Tobacco, Inc. Method for transforming monocotyledons
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
HUT70467A (en) 1992-07-27 1995-10-30 Pioneer Hi Bred Int An improved method of agrobactenium-mediated transformation of cultvred soyhean cells
DE4228457A1 (de) 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
GB9222888D0 (en) 1992-10-30 1992-12-16 British Tech Group Tomography
US5846709A (en) 1993-06-15 1998-12-08 Imclone Systems Incorporated Chemical process for amplifying and detecting nucleic acid sequences
FR2708288B1 (fr) 1993-07-26 1995-09-01 Bio Merieux Procédé d'amplification d'acides nucléiques par transcription utilisant le déplacement, réactifs et nécessaire pour la mise en Óoeuvre de ce procédé.
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US5648240A (en) 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
DE69527355T2 (de) 1994-05-28 2003-03-06 Tepnel Medical Ltd., Manchester Herstellung von nukleinsaeurekopien
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5942391A (en) 1994-06-22 1999-08-24 Mount Sinai School Of Medicine Nucleic acid amplification method: ramification-extension amplification method (RAM)
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US6008341A (en) 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5935825A (en) 1994-11-18 1999-08-10 Shimadzu Corporation Process and reagent for amplifying nucleic acid sequences
US6770278B1 (en) 1994-12-02 2004-08-03 Central Biomedia, Inc. Methods of making and using immunoglobulin (Ig) compositions
US5548066A (en) 1994-12-02 1996-08-20 Central Biomedia, Inc. Failure of passive transfer immune serum and method of making same
US5843650A (en) 1995-05-01 1998-12-01 Segev; David Nucleic acid detection and amplification by chemical linkage of oligonucleotides
EP0857214A1 (en) 1995-10-16 1998-08-12 Smithkline Beecham Plc Novel saliva binding protein
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
US6737248B2 (en) 1996-01-05 2004-05-18 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences
US5612473A (en) 1996-01-16 1997-03-18 Gull Laboratories Methods, kits and solutions for preparing sample material for nucleic acid amplification
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
AU3126097A (en) 1996-05-16 1997-12-05 The Texas A & M University System Collagen binding protein compositions and methods of use
US5939291A (en) 1996-06-14 1999-08-17 Sarnoff Corporation Microfluidic method for nucleic acid amplification
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
US6294177B1 (en) 1996-09-11 2001-09-25 Nabi Staphylococcus aureus antigen-containing whole cell vaccine
US5849546A (en) 1996-09-13 1998-12-15 Epicentre Technologies Corporation Methods for using mutant RNA polymerases with reduced discrimination between non-canonical and canonical nucleoside triphosphates
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
KR100564268B1 (ko) 1996-10-23 2006-03-27 와이어쓰 백신
US5849497A (en) 1997-04-03 1998-12-15 The Research Foundation Of State University Of New York Specific inhibition of the polymerase chain reaction using a non-extendable oligonucleotide blocker
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US5866366A (en) 1997-07-01 1999-02-02 Smithkline Beecham Corporation gidB
US5916776A (en) 1997-08-27 1999-06-29 Sarnoff Corporation Amplification method for a polynucleotide
US6756361B1 (en) 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5932451A (en) 1997-11-19 1999-08-03 Incyte Pharmaceuticals, Inc. Method for unbiased mRNA amplification
IL122829A (en) 1997-12-31 2000-06-29 Maabarot Products Ltd Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
AU758019B2 (en) 1998-07-10 2003-03-13 U.S. Medical Research Institute Of Infectious Diseases Anthrax vaccine
CA2341177A1 (en) 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
WO2000012689A1 (en) 1998-08-31 2000-03-09 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Polypeptides and polynucleotides from coagulase-negative staphylococci
US6355625B1 (en) 1998-09-14 2002-03-12 Nabi Compositions of β-glucans and specific IGIV
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
AU1478301A (en) 1999-11-09 2001-06-06 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
DE60040740D1 (de) 1999-12-03 2008-12-18 Celltech Chiroscience Ltd VERWENDUNG OF INTERLEUkIN-1 MUTEIN ALS IMPFSTOFFADJUVANS
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
SE0000514D0 (sv) 2000-02-17 2000-02-17 Biostapro Ab A 52 kDa protein from coagulase negative staphylococci and fragments
CA2404260A1 (en) * 2000-03-21 2001-09-27 Elitra Pharmaceuticals, Inc. Identification of essential genes in prokaryotes
GB0014907D0 (en) 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
SE0003573D0 (sv) * 2000-10-04 2000-10-04 Bengt Guss Method and means for producing novel von Willebrand factor binding proteins and their use in biotechnology
WO2002038175A1 (en) 2000-11-07 2002-05-16 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US20020169288A1 (en) 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
WO2002077183A2 (en) * 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
EP1412379B1 (en) * 2001-08-02 2012-01-25 The University Of Sheffield Vaccine
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7115264B2 (en) 2001-11-05 2006-10-03 Inhibitex Monoclonal antibodies to the fibronectin binding protein and method of use in treating or preventing infections
US7157443B2 (en) 2001-12-11 2007-01-02 Merck & Co., Inc. Staphylococcus aureus exopolysaccharide and process
WO2004043407A2 (en) 2002-11-12 2004-05-27 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
CN100351260C (zh) 2002-11-12 2007-11-28 布赖汉姆妇女医院 葡萄球菌感染的多糖疫苗
JP2008513406A (ja) * 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
KR100654455B1 (ko) * 2005-05-26 2006-12-06 삼성전자주식회사 확장형 자막 파일을 이용하여 부가정보를 제공하는 장치 및방법
KR20070082442A (ko) * 2006-02-16 2007-08-21 정재욱 폴더형 개인휴대단말기
KR100771584B1 (ko) * 2006-02-16 2007-10-30 다이노나(주) 메치실린-내성 황색포도상구균 특이적 항체, 상기 항체를이용하는 메치실린-내성 황색포도상구균 탐지방법, 및탐지키트
MY148405A (en) * 2006-03-30 2013-04-30 Glaxosmithkline Biolog Sa Immunogenic composition
AR060187A1 (es) * 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Composicion inmunogenica
US9526774B1 (en) * 2006-11-06 2016-12-27 Microvax, Llc Methods and compositions for suppressing virulence of methicillin resistant Staphylococcus aureus
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
US9181329B2 (en) * 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CA2739581A1 (en) * 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial eap, emp, and/or adsa proteins
JP5789250B2 (ja) * 2009-04-03 2015-10-07 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ プロテインＡ（ＳｐＡ）変種に関連する組成物および方法
WO2010119343A2 (en) * 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
WO2010142906A2 (fr) * 2009-06-10 2010-12-16 Ingen Biosciences Antigenes proteiques destines au serodiagnostic des infections a staphylococcus aureus notamment sur protheses osteo-articulaires
US20140037650A1 (en) * 2009-07-24 2014-02-06 University Of Chicago Compositions and methods related to antibodies to staphylococcal proteins isda or isdb
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
FR2957821B1 (fr) 2010-03-24 2014-08-29 Inst Francais Du Petrole Nouvelle zone de regeneration du catalyseur divisee en secteurs pour unites catalytiques regeneratives
CA2803298C (en) * 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (en) * 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
US9085631B2 (en) * 2011-04-08 2015-07-21 Nov Vac APS Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureus
US8945588B2 (en) * 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2744517B1 (en) * 2011-08-15 2019-03-13 The University of Chicago Compositions and methods related to antibodies to staphylococcal protein a
EP2793939A1 (en) * 2011-12-23 2014-10-29 Novartis AG Stable compositions for immunising against staphylococcus aureus
WO2013162751A1 (en) * 2012-04-26 2013-10-31 University Of Chicago Compositions and methods related to antibodies that neutralize coagulase activity during staphylococcus aureus disease
NZ702285A (en) * 2012-04-26 2016-07-29 Univ Chicago Staphylococcal coagulase antigens and methods of their use
WO2014179744A1 (en) * 2013-05-03 2014-11-06 The University Of Chicago Staphylococcus live cell vaccines
US9353189B2 (en) * 2014-01-24 2016-05-31 William R Church Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same
PL236568B1 (pl) * 2014-08-31 2021-01-25 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepy Staphylococcus aureus do produkcji monoklonalnych preparatów fagowych pozbawionych zanieczyszczeń plazmidowym DNA
CA2992795A1 (en) * 2015-08-06 2017-02-09 Ares Genetics Gmbh Genetic testing for alignment-free predicting resistance of microorganisms against antimicrobial agents
JP7117244B2 (ja) * 2016-02-12 2022-08-12 ザ・ユニバーシティ・オブ・シカゴ 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011127032A1 (en) * 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Contribution of Coagulases towards Staphylococcus aureusDisease and Protective Immunity";Alice G. Cheng;《PLos Pathogens》;20100805;第6卷(第8期);第5页右栏第11-17行，第13页右栏第11行到第14页左栏第11行，图4 *
"The von Willebrand factor-binding protein (vWbp) ofStaphylococcus aureus is a coagulase.";Joakim Bjerketorp;《FEM Microbiology Letter》;20040407;第234卷;309-314 *

Also Published As

Publication number Publication date
WO2013162746A1 (en) 2013-10-31
HRP20201127T1 (hr) 2020-11-27
EP2844275A4 (en) 2016-10-05
PL2844275T3 (pl) 2021-03-08
US9968668B2 (en) 2018-05-15
EP3805395A1 (en) 2021-04-14
AU2013252883A1 (en) 2014-12-04
EP2844275B1 (en) 2020-05-13
US10857220B2 (en) 2020-12-08
ES2806945T3 (es) 2021-02-19
JP6670106B2 (ja) 2020-03-18
AU2013252883B2 (en) 2018-05-17
DK2844275T3 (da) 2020-07-13
US20180243394A1 (en) 2018-08-30
CN104768572A (zh) 2015-07-08
BR112014026861A2 (pt) 2018-05-15
US20150273040A1 (en) 2015-10-01
EP2844275A1 (en) 2015-03-11
CA2910319A1 (en) 2013-10-31
US20210093706A1 (en) 2021-04-01
JP2015515280A (ja) 2015-05-28
HK1207571A1 (en) 2016-02-05
JP2018121640A (ja) 2018-08-09
CA2910319C (en) 2022-06-14
NZ702285A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
US20240190927A1 (en) COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SpA) VARIANTS
CN102612523B (zh) 与蛋白a(spa)变体相关的组合物和方法
US8945588B2 (en) Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
US9095540B2 (en) Methods and compositions involving protective staphylococcal antigens
US10857220B2 (en) Staphylococcal coagulase antigens and methods of their use
CN103314008B (zh) 涉及保护性葡萄球菌抗原的方法和组合物
AU2015202158B2 (en) Compositions and methods related to protein a (spa) variants
HK1207571B (en) Staphylococcal coagulase antigens and methods of their use
HK1162533B (en) Compositions and methods related to protein a (spa) variants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CI02 Correction of invention patent application

Correction item: Description

Correct: Correct

False: Error

Number: 27

Page: Description

Volume: 31

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210824

CF01 Termination of patent right due to non-payment of annual fee